Office of Sciences

The Mission of the Office of Sciences at the TTUHSC School of Pharmacy is to coordinate the school's research needs with our state-of-the-art scientific and technical support and to promote and accelerate research grant applications and new award set-up.

Office of Sciences
TTUHSC School of Pharmacy
1406 S. Coulter St.
Amarillo, Texas 79106

Department Email: SOPOfficeOfSciences@ttuhsc.edu

The Office of Sciences is available to all faculty on each of the four TTUHSC School of Pharmacy campus sites: Amarillo, Abilene, Dallas/Fort Worth and Lubbock. Our purpose is to act as a resource for the granting process, facilitate research and administer internal research programs.

The Office of Sciences provides and oversees the following programs and services:

Seventeenth Annual Research Days

June 13-14, 2018 at the Amarillo Civic Center Heritage Room
This annual event is a wonderful opportunity for School of Pharmacy's Faculty, Post-Doctoral Research Associates, Graduate students, Residents, and Pharm.D. students to come together from all four campuses to talk about research and build collaborations and friendships. Research Days consists of poster competitions, keynote addresses, podium presentations on current research, breakout sessions, and the annual dinner. MORE

High Impact Publications

Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex.

Dr. Magdalena Karbowniczek, Associate Professor in the Department of Immunotheapeutics and Biotechnology in Abilene, and her team’s recent publication, “Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex." Dr. Karbowniczek’s laboratory studies the cellular and molecular mechanisms behind a rare disease tuberous sclerosis complex (TSC), which is caused by the inactivating mutations in tumor suppressor genes TSC1 and TSC2. The manuscript is scheduled for publication this year in the cancer journal Oncogene. (Impact Factor 8.459)... READ ARTICLE

Can also be found in BioQuick News

Penfloridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis.

Dr. Sanjay K. Srivastava, Professor of Biomedical Sciences and Associate Dean for Office of Sciences, and his team's recent publication, "Penfloridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis." Cancer Research, 76, 877-890, 2016. (Impact Factor 9.329) PMID: 26627008

Metastasis of breast cancer, especially to the brain, is the major cause of mortality. The inability of anticancer agents to cross the blood-brain-barrier represents a critical challenge for successful treatment. In the current study, Dr. Srivastava and his team investigated the antimetastatic potential of penfluridol, an antipsychotic drug frequently prescribed for schizophrenia with anticancer activity. His group demonstrated that penfluridol induced apoptosis and reduced the survival of several metastatic triple-negative breast cancer (TNBC) cell lines and suppressed tumor growth in various models.... READ ARTICLE